When Alessia Morichi stepped onto the tarmac at San Francisco International Airport in late 2023, she wasn’t just carrying a suitcase and a dream—she was transporting a quiet revolution in women’s health, encoded in lines of Python and fueled by a personal frustration that had simmered for years. Her app, Fertilità Mappata, doesn’t just track ovulation; it maps the invisible topography of female fertility by integrating hormonal data, lifestyle patterns, and environmental exposures into a dynamic, AI-driven fertility landscape. What began as a side project during her tenure at Google’s Zurich office has now become a focal point in a growing debate: Can technology democratize reproductive agency in an era where access to fertility care remains starkly unequal?
The story matters now given that fertility is no longer a private matter confined to clinic waiting rooms—it’s a public health imperative with economic ripple effects. In Italy, where Morichi began her journey, the birth rate hit a historic low of 1.24 children per woman in 2023, according to ISTAT, threatening long-term demographic stability. Across the Atlantic, Silicon Valley’s fertility tech sector attracted over $1.2 billion in venture capital in 2025 alone, per PitchBook data, yet fewer than 15% of funded startups were founded by women, and even fewer addressed non-clinical fertility tracking. Morichi’s bridge between these two worlds—her Italian roots in public health innovation and her Californian immersion in scalable tech—offers a rare case study in transatlantic knowledge transfer. But beneath the inspiring narrative lies a critical information gap: How exactly does an app that maps fertility actually work, and what safeguards exist to prevent the very biases it aims to overcome?
To understand the technology, one must first grasp what “mapping fertility” entails. Unlike conventional period trackers that rely on calendar averages or basal body temperature, Fertilità Mappata uses a multimodal approach. Users input daily metrics—sleep quality, stress levels via wearable integration, nutrition logs, and even air quality indices from their zip code—whereas optional saliva strips (analyzed via a companion device) provide real-time estrogen and luteinizing hormone surges. The app’s proprietary algorithm, trained on over 500,000 anonymized cycles from users across Europe and North America, identifies subtle patterns invisible to traditional methods. “We’re not predicting ovulation,” explains Dr. Elena Rossi, a reproductive endocrinologist at San Raffaele Hospital in Milan who consulted on the app’s clinical validation. “We’re mapping the *fertile window* as a probabilistic cloud—shaped by biology, yes, but also by sleep deprivation, cortisol spikes, and even weekend alcohol consumption. It’s fertility as a dynamic system, not a static event.”
“What Alessia has built isn’t just another tracker—it’s a digital twin of the menstrual ecosystem. That’s paradigm-shifting for preventive reproductive health.”
— Dr. Elena Rossi, Reproductive Endocrinologist, San Raffaele Hospital
The historical context is equally vital. For decades, fertility research has been hampered by a male-centric biomedical model. As historian of science Dr. Rebecca Jordan-Young notes in her seminal work Brain Storm, the assumption that menstrual cycles are “noise” to be filtered out delayed meaningful study of female physiology until the 1980s. Even today, women comprise less than 30% of participants in early-phase clinical trials, per FDA reports. Fertilità Mappata’s approach subtly challenges this legacy by treating the female body not as a problem to be fixed, but as a complex, adaptive system worthy of precision mapping—much like how Silicon Valley models traffic flow or power grids. Yet this innovation arrives amid growing scrutiny of femtech’s data practices. A 2024 audit by the Electronic Frontier Foundation found that 68% of fertility apps shared sensitive health data with third-party marketers, often without explicit user consent. Morichi insists her app avoids this pitfall: “We built on a zero-trust architecture from day one. Hormonal data never leaves the user’s device unless they opt into anonymized research—and even then, it’s differentially privatized.”
What the original source didn’t reveal is how Morichi’s journey reflects a broader shift in global innovation ecosystems. Her time at Google’s Digital Wellbeing team in London exposed her to behavioral nudges that encourage healthier habits—insights she now applies to fertility literacy. But moving to California wasn’t just about access to capital; it was about adopting a mindset where failure is iterated, not stigmatized. “In Italy, we excel at deep, thoughtful design,” she told Wired Italia in a 2024 interview. “In the Valley, I learned to ship fast, learn faster, and scale what works. Fertility care needs both.” This hybrid ethos is evident in the app’s development: clinical trials were run in collaboration with Bologna’s Policlinico Sant’Orsola, while the AI backbone was refined using Google Cloud’s Vertex AI during her sabbatical.
The macro-economic implications are profound. A 2023 McKinsey analysis estimated that improving access to fertility education and early intervention could add $400 billion annually to global GDP by reducing untreated infertility-related productivity loss. Yet public health systems rarely invest in preventive fertility literacy—most spending kicks in only after conception fails. Apps like Fertilità Mappata could shift this paradigm, empowering users to seek help earlier. In regions with limited OB-GYN access—such as rural Sicily or California’s Central Valley—such tools may become de facto first points of contact. Still, challenges linger. Digital literacy gaps, distrust in AI-driven health advice, and the risk of algorithmic gatekeeping (where only those with wearables and smartphones benefit) threaten to exacerbate existing inequities. As Dr. Amara Enyia, policy director at the Shriver Center on Poverty Law, warns: “We must ask: Who gets to be mapped? And who gets left off the terrain?”
“Technology doesn’t erase structural barriers—it can amplify them if we’re not deliberate. Fertility apps must be designed with Medicaid recipients, shift workers, and undocumented migrants in mind, or they’ll just be another luxury for the privileged.”
— Dr. Amara Enyia, Policy Director, Shriver Center on Poverty Law
Today, as Fertilità Mappata prepares for FDA clearance as a Class II medical device—a milestone Morichi hopes to achieve by late 2026—the app stands at an inflection point. Its success won’t be measured solely in downloads or funding rounds, but in whether it helps close the fertility knowledge gap that disproportionately affects low-income women and women of color. For Morichi, the mission remains deeply personal: “I built this because I wanted to understand my own body better. Now I want every woman to have that clarity—not as a privilege, but as a baseline.”
The takeaway is clear: Mapping fertility isn’t just about predicting pregnancy—it’s about reclaiming agency over a biological process long shrouded in mystery, and mismanagement. As femtech evolves from niche novelty to mainstream health infrastructure, the real innovation may not lie in the algorithms, but in who gets to shape them. Will the next generation of fertility tools be designed by those who’ve sat anxiously in clinic waiting rooms, or will they continue to be built in boardrooms far removed from lived experience? The answer will determine whether apps like Fertilità Mappata truly democratize reproductive health—or simply digitize its disparities.
What role should public health systems play in integrating fertility literacy tools like this into preventive care—especially in underserved communities? Share your thoughts below.
